Log in

Relevant bibliographies by topics / Ado-trastuzumab emtansine

Contents

Journal articles
Book chapters
Conference papers

Academic literature on the topic 'Ado-trastuzumab emtansine'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ado-trastuzumab emtansine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ado-trastuzumab emtansine"

1

Corrigan, Patricia A., Teresa A. Cicci, Jessica Johnston Auten, and Denise K. Lowe. "Ado-trastuzumab Emtansine." Annals of Pharmacotherapy 48, no. 11 (2014): 1484–93. http://dx.doi.org/10.1177/1060028014545354.

Full text

Abstract:

Objective: To review the pharmacology, pharmacokinetics, efficacy, adverse effects, drug-drug interactions, dosage and administration, and formulary considerations for ado-trastuzumab emtansine. Data Sources: Sources of information were identified through a PubMed search (1966 to June 2014) using the key terms ado-trastuzumab emtansine, trastuzumab-DM1, trastuzumab-MCC-DM1, and T-DM1. Other information was obtained from clinicaltrials.gov, product labeling, and press releases. Study Selection and Data Extraction: All English-language clinical trials and abstracts evaluating ado-trastuzumab emt

APA, Harvard, Vancouver, ISO, and other styles

2

Lavingia, Viraj, Vipulkumar Thummar, and Priya Mehta. "Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2–overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study." SAGE Open Medical Case Reports 10 (January 2022): 2050313X2211374. http://dx.doi.org/10.1177/2050313x221137447.

Full text

Abstract:

Biliary tract cancers are clinically and genetically heterogeneous cancer type with a worst prognosis among gallbladder adenocarcinoma patients. Systemic therapeutic options for metastatic biliary tract cancers are fewer, and there are limited treatment choices for the patients who progress on first line apart from symptomatic treatment. Thus, a biomarker-guided personalized treatment approach needs to be explored among biliary tract cancer subtypes. We encountered a case of 53-year-old male patient with human epidermal growth factor receptor 2 (HER2, ERBB2) positive metastatic gallbladder can

APA, Harvard, Vancouver, ISO, and other styles

3

Andre Manov MD, Weston Truman DO, Alex Chao DO, and Amanpreet Kaur MD. "Description of patient with telangiectasis and palmar erythema without any structural liver changes or changes of liver laboratory parameters due to treatment of Her -2 -positive breast cancer with Ado-Trastuzumab-Emtansine." World Journal of Advanced Research and Reviews 11, no. 2 (2021): 169–72. http://dx.doi.org/10.30574/wjarr.2021.11.2.0373.

Full text

Abstract:

Ado- Trastuzumab-Emtansine is approved by EMA and FDA for treatment of HER-2-positive metastatic breast cancer. The drug combines the cytotoxic activity of emtansine with trastuzumab [1,2,3]. Here we are describing 50- year old woman with 3-ple positive left breast cancer with metastasis to left axillary lymph nodes treated with the drug. The patient had normal liver and spleen structure on CT of the abdomen with I.V. contrast, along with a normal liver function test. However she did have a mild elevation of her indirect bilirubin after the initiation of the drug. Despite the normal liver and

APA, Harvard, Vancouver, ISO, and other styles

4

Andre, Manov MD, Truman DO Weston, Chao DO Alex, and Kaur MD Amanpreet. "Description of patient with telangiectasis and palmar erythema without any structural liver changes or changes of liver laboratory parameters due to treatment of Her -2 -positive breast cancer with Ado-Trastuzumab-Emtansine." World Journal of Advanced Research and Reviews 11, no. 2 (2021): 169–72. https://doi.org/10.5281/zenodo.5336679.

Full text

Abstract:

Ado- Trastuzumab-Emtansine is approved by EMA and FDA for treatment of HER-2-positive metastatic breast cancer. The drug combines the cytotoxic activity of emtansine with trastuzumab [1,2,3]. Here we are describing 50- year old woman with 3-ple positive left breast cancer with metastasis to left axillary lymph nodes treated with the drug. The patient had normal liver and spleen structure on CT of the abdomen with I.V. contrast, along with a normal liver function test. However she did have a mild elevation of her indirect bilirubin after the initiation of the drug. Despite the normal liver and

APA, Harvard, Vancouver, ISO, and other styles

5

Solimando, Dominic A., and J. Aubrey Waddell. "Ado-Trastuzumab Emtansine and Radium 223 Dichloride." Hospital Pharmacy 48, no. 9 (2013): 729–33. http://dx.doi.org/10.1310/hpj4809-729.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Muzaffar, Mahvish, Jingquan Jia, Darla Liles, Musharraf Naveed, and Anita Kumari. "Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine." American Journal of Therapeutics 23, no. 2 (2016): e572-e574. http://dx.doi.org/10.1097/mjt.0000000000000179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Shafaee, Maryam Nemati, Ahmed A. Salahudeen, and Vicente Valero. "Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation." Journal of Oncology Practice 13, no. 8 (2017): 555–56. http://dx.doi.org/10.1200/jop.2016.020198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Shukla, Navika D., Ryan S. Chiang, and Alexander D. Colevas. "Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam‐Trastuzumab Deruxtecan." Journal of the National Comprehensive Cancer Network 20, no. 2 (2022): 102–4. http://dx.doi.org/10.6004/jnccn.2021.7089.

Full text

Abstract:

HER2 mutations have been shown to be targetable in select cases of salivary gland cancers with overexpression or amplification of the HER2 oncogene. Fam-trastuzumab deruxtecan, a novel antibody–drug conjugate that combines trastuzumab with a topoisomerase I inhibitor, has recently demonstrated efficacy as a third-line agent in HER2-overexpressing breast cancer after trastuzumab failure. These promising results in breast cancer suggest a potential paradigm for use in other tumors with known HER2 alterations, including salivary gland cancer. This report describes a 67-year-old man with HER2-posi

APA, Harvard, Vancouver, ISO, and other styles

9

Traynor, Kate. "Ado-trastuzumab emtansine approved for advanced breast cancer." American Journal of Health-System Pharmacy 70, no. 7 (2013): 562. http://dx.doi.org/10.2146/news130023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Maurea, N., C. Coppola, G. Piscopo, et al. "Ranolazine partially blunts ado trastuzumab emtansine related cardiotoxicity." Annals of Oncology 27 (October 2016): vi7. http://dx.doi.org/10.1093/annonc/mdw362.25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Ado-trastuzumab emtansine"

1

Luo, Yun, Jérôme J. Lacroix, and Sunil Prabhu. "Ado-Trastuzumab Emtansine." In Antibody-Drug Conjugates. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13081-1_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Luo, Yun, Jérôme J. Lacroix, and Sunil Prabhu. "Ado-Trastuzumab Emtansine." In AAPS Advances in the Pharmaceutical Sciences Series. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-83005-1_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chowdhury, Ruhe, and Paul Ellis. "Trastuzumab (Herceptin®) and Ado-Trastuzumab Emtansine (Kadcyla®): Treatments for HER2-Positive Breast Cancer." In Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch72.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Filippini, Daria Maria, and Christophe Le Tourneau. "Therapeutic Potential of Antibody-Drug Conjugates in Head and Neck Cancers." In Critical Issues in Head and Neck Oncology. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-84539-0_21.

Full text

Abstract:

Abstract Recurrent/metastatic head and neck cancers remain incurable diseases despite the development of molecularly targeted therapies and immunotherapies. The antibody-drug conjugates (ADCs) are emerging as a novel therapeutic class which integrate the precision of monoclonal antibodies with a cytotoxic drug, referred to as the payload, through a chemical linker, with the aim of selectively delivering this highly toxic payload directly to the cancer cells and, thereby, enhancing the therapeutic index. Various ADCs have been explored and validated across various solid malignancies: the first

APA, Harvard, Vancouver, ISO, and other styles

5

Simpson, Michelle C., and Eric G. Schaefer. "ADO-Trastuzumab Emtansine." In Extended Stability for Parenteral Drugs. ASHP, 2022. http://dx.doi.org/10.37573/9781585286720.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"ADO-Trastuzumab Emtansine." In Extended Stability for Parenteral Drugs. American Society of Health-System Pharmacists, 2017. http://dx.doi.org/10.37573/9781585285280.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"Ado-Trastuzumab Emtansine." In ASHP® Injectable Drug Information™. ASHP, 2024. https://doi.org/10.37573/9781585287444.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ado-trastuzumab emtansine"

1

Gadi, VK, BS Butler, J. Corson, and SJ Slichter. "Abstract OT3-01-11: Thrombokinetic studies of ado-trastuzumab emtansine (T-DM1)." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-ot3-01-11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mortimer, JE, JR Bading, P. Frankel, et al. "Abstract PD4-12: Use of64Cu-DOTA-trastuzumab positron emission tomography (PET) to predict response to ado-trastuzumab emtansine (TDM1)." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-pd4-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Bob T., Marjorie Zauderer, Jamie Chaft, et al. "Abstract CT225: Ado-trastuzumab emtansine forHER2amplified or HER2 overexpressed cancers: A phase II “basket” trial." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-ct225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Xia, Yang, Xiu Huang, Rui Jin, Wen Li, and Huahao Shen. "The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4669.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Báez-Vallecillo, L., A. Singareeka Raghavendra, K. Hess, et al. "Abstract P4-21-20: Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p4-21-20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ferraro, Gino B., Vasileios Askoxylakis, David P. Kodack, et al. "Abstract A48: Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice." In Abstracts: AACR Special Conference on Tumor Metastasis; November 30-December 3, 2015; Austin, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tummet15-a48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Askoxylakis, V., G. Ferraro, D. Kodack, M. Badeaux, and R. Jain. "Abstract P6-17-02: Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p6-17-02.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kida, K., J. Lee, H. Liu, et al. "Abstract P3-10-23: Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p3-10-23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Goertz, Hans-Peter, Oscar Herrera-Restrepo, Elizabeth Wehler, Pinar Bilir, Vincent Antao, and Gurleen Singh Jhuti. "Abstract P6-13-01: Cost-effectiveness of ado-trastuzumab emtansine (T-DM1) versus trastuzumab (H) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the US." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p6-13-01.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Verma, S., J. Shahidi, C. Lee, K. Wang, and J. Cortes. "Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ot2-07-03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!